Skip to content
Provisions in the Inflation Reduction Act (IRA) make it easier for people covered by Medicare Part D to pay for medicine, but continued government […]
CMS must flesh out plan to ease out-of-pocket drug costs, report says Read More »
Washington, D.C., is all about who you know—and coalitions of people and groups with the same goals are key to getting stuff done. During
Patient advocacy coalitions can create change – here’s how Read More »
The federal 340B Drug Pricing Program is starting to get a great deal of attention—for all the wrong reasons. The program was started in
Hospitals and pharmacies profit as 340B drives up patients’ drug costs Read More »
PDAB – which stands for Prescription Drug Affordability Board – is an acronym that you might hear more lately, as more and more states
PDABs bring the problem of drug price controls to the state level Read More »
The US House of Representatives passed the Senate’s Inflation Reduction Act on Friday, by a party-line vote of 220-207. All Democrats voted in favor
Congress passed drug price controls, sends bill to Biden for signature Read More »
Proposed drug price controls will disrupt the vibrant US biotech ecosystem, according to Vital Transformation CEO Duane Schulthess. He spoke during an online briefing
Drug price control plan will disrupt biotech ecosystem, expert says Read More »
On June 22, the Senate Commerce Committee approved BIO-supported legislation intended to increase transparency of the business practices of pharmacy benefit managers (PBMs), which
Senate Committee advances PBM transparency legislation Read More »
The U.S. Federal Trade Commission (FTC) announced last week that it will investigate the “prescription drug middleman industry,” demanding information and records regarding the
FTC will investigate six largest pharmacy benefit managers Read More »
A bipartisan bill introduced in the Senate would take aim at the opaque pharmacy benefit manager (PBM) system to improve transparency in a scheme
Bill would add transparency to pharmacy benefit manager system Read More »
How much do U.S. hospitals mark up the price of parenteral cancer therapies for patients with private health insurance? Researchers set out to answer
New study: Hospitals hike cancer drug prices Read More »
